Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

NCT01650350 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Study stopped 10/24/13 secondary to lack of patients/slow enrollment

Conditions

Melanoma
Prostate Cancer
Renal Cancer

Interventions

DRUG: Naltrexone

Sponsor

Brown University